These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 15949121

  • 1. High participation rates are not necessary for cost-effective colorectal cancer screening.
    Howard K, Salkeld G, Irwig L, Adelstein BA.
    J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS, Liao CS, Chang SH, Lai HC, Chen TH.
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France.
    Berchi C, Bouvier V, Réaud JM, Launoy G.
    Health Econ; 2004 Mar; 13(3):227-38. PubMed ID: 14981648
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF, Russo MW, Biddle AK, Simpson KN, Ransohoff DF, Sandler RS.
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [Abstract] [Full Text] [Related]

  • 13. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
    Hagen A, Hessabi HK, Gorenoi V, Schönermark MP.
    Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
    [Abstract] [Full Text] [Related]

  • 14. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F, Boemo C, Ardizzoia A, Costa M, Carzaniga P, Ilardo A, Moretti R, Cremaschini M, Parente EM, Pirola ME.
    Endoscopy; 2013 Jan; 45(1):27-34. PubMed ID: 23254404
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of capsule endoscopy in screening for colorectal cancer.
    Hassan C, Zullo A, Winn S, Morini S.
    Endoscopy; 2008 May; 40(5):414-21. PubMed ID: 18302080
    [Abstract] [Full Text] [Related]

  • 17. A literature review of assumptions on test characteristics and adherence in economic evaluations of colonoscopy and CT-colonography screening.
    van Gils P, van den Berg M, van Kranen H, de Wit AG.
    Eur J Cancer; 2009 Jun; 45(9):1554-9. PubMed ID: 19261464
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
    Grazzini G, Ciatto S, Cislaghi C, Castiglione G, Falcone M, Mantellini P, Zappa M, Working Group of Regional Reference Centre for Oncological Screening of Tuscany.
    J Med Screen; 2008 Jun; 15(4):175-81. PubMed ID: 19106257
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.